

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Naylor et al.
U.S. Serial No.: Not Yet Assigned;
Continuation-In-Part of U.S.S.N 09/787,562, filed July 6, 2001
Filed : Herewith
For : POLYNUCLEOTIDE CONSTRUCTS AND USES THEREOF

745 Fifth Avenue
New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EV 287821807 US

Date of Deposit: March 26, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Charles Jackson
(Typed or printed name of person mailing paper or fee)

Charles Jackson
(Signature of person mailing paper or fee)

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is invited to the following documents, which are set forth in the accompanying PTO-1449 form, submitted in duplicate. To the extent that these documents were forwarded to or cited by the Examiner in the predecessor application (U.S.S.N. 09/787,562, filed on July 6, 2001), a copy of each document should be in the predecessor application files. Accordingly, the only documents being forwarded with this Information Disclosure Statement are the references that were not previously cited.


This Information Disclosure Statement is not a representation that the documents cited herein are considered most pertinent, or that a search has been undertaken, or that any of the cited documents are indeed prior art. The Examiner is invited to undertake an independent search.

Applicants respectfully request that the Examiner consider and make of record the documents cited herein and that a copy of Form PTO-1449, initialed by the Examiner, be returned to Applicants' attorneys.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicants

By:


Thomas J. Kowalski
Reg. No. 32,147

Anne-Marie C. Yvon, Ph.D.
Reg. No. 52,390
Phone (212) 588-0800

Based on Form PTO-1449 (3/90)				ATTY. DOCKET NO. 674523-2029.1		SERIAL NO. TBA	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT Naylor, et al.			
				FILING DATE Herewith		GROUP TBA	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,834,306	11/1998	Webster et al.			
	AB	5,942,434	08/1999	Ratcliffe et al.			
	AC	6,265,390	07/2001	Ratcliffe et al.			
	AD	2002/0183253	12/2002	Brazzell et al.			
	AE	2002/0194630	12/2002	Manning, Jr., et al.			
	AF	2003/0082159	05/2003	Appukuttan, et al.			
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL	EO 0 745 131	1/2/2003	EPO				
	AM							
	AN							
	AO							
	AP							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AQ		Mistry, et al., <i>ARVO Annual Meeting Abstract Search and Program Planner</i> , 2003: Abstract No. 1081, "Hypoxia - Regulated Transgene Expression in Experimental Retinal and Choroidal Neovascularisation"
	AR		Bainbridge, et al. 2003 <i>Gene Therapy</i> , 10:1049-1054, "Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularisation"
	AS		
	AT		
	AU		
	AV		

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

9192.16USWO

Application Number:

09/787,562

Applicant: BINLEY et al.

Filing Date: March 19, 2001

Group Art Unit: Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 91/00047	January 10, 1991	WIPO				
	WO 91/00047	July 11, 1991	WIPO				
	WO 94/26914	November 24, 1994	WIPO			Abstract	
	WO 94/28152	December 8, 1994	WIPO			Abstract	
	WO 95/02697	January 26, 1995	WIPO			Abstract	
	WO 95/03400	February 2, 1995	WIPO				
	WO 95/21927	August 17, 1995	WIPO				
	WO 95/27071	October 12, 1995	WIPO				
	WO 96/09400	March 28, 1996	WIPO				
	WO 96/10088	April 4, 1996	WIPO			Abstract	
	WO 96/20276	July 4, 1996	WIPO				
	WO 96/22378	July 25, 1996	WIPO			Abstract	
	WO 96/25506	August 22, 1996	WIPO			Abstract	
	WO 96/33623	October 31, 1996	WIPO				
	WO 97/12622	April 10, 1997	WIPO				
	WO 97/17457	May 15, 1997	WIPO				
	WO 97/27310	July 31, 1997	WIPO				
	WO 98/05754	February 12, 1998	WIPO				
	WO 98/05759	February 12, 1998	WIPO				
	WO 98/09985	March 12, 1998	WIPO				
	WO 98/15294	April 16, 1998	WIPO				
	WO 98/18815	May 7, 1998	WIPO				
	WO 98/19695	May 14, 1998	WIPO				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

9192.16USWO

Application Number:

09/787,562

Applicant: BINLEY et al.

Filing Date: March 19, 2001

Group Art Unit: Unknown

	WO 98/30707	July 16, 1998	WIPO				
	WO 98/31701	July 23, 1998	WIPO				
	WO 99/15684	April 1, 1999	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Ace et al., 1989, <i>Journal of Virology</i> , 63:2260-2269, "Construction and Characterization of a Herpes Simplex Virus Type 1 Mutant Unable to Transduce Immediate-Early Gene Expression"
		Becker et al., 1998, <i>Human Gene Therapy</i> , 9:1561-1570, "Correction of Respiratory Burst Activity in X-linked Chronic Granulomatous Cells to Therapeutically Relevant Levels after Gene Transfer into Bone Marrow CD34+ Cells"
		Beerepoot et al., 1996, <i>Cancer Research</i> , 56:3747-3751, "Up-regulation of Vascular Endothelial Growth Factor Production by Iron Chelators"
		Bender et al., 1987, <i>Journal of Virology</i> , 61:1639-1646; "Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the gag Region"
		Binley et al., 1999, <i>Gene Therapy</i> , 6:1721-1727, "An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer"
		Julie Blatt, 1994, <i>Anticancer Research</i> , 14:2109-2112, "Deferoxamine in Children with Recurrent Neuroblastoma"
		Blomer et al., 1997, <i>Journal of Virology</i> , 71: 6641-6649, "Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector"
		Boast et al., 1999, <i>Human Gene Therapy</i> , 10:2197-2208, "Characterization of Physiologically Regulated Vectors for the Treatment of Ischemic Disease"
		Bodine et al., 1992, <i>Exp. Hematol</i> , 1991:206-212, "Survival and Retrovirus Infection of Murine Hematopoietic Stem Cells in vitro: Effects of 5-FU and Method of Infection"
		Bregni et al., 1998, <i>Gene Therapy</i> , 5:465-472, "Adenovirus vectors for gene transduction into mobilized blood CD34+ cells"
		Burke et al., 1997, <i>European Journal of Cancer</i> , 33:1114-1121, "Interferon Gamma Induces Cell Cycle Arrest and apoptosis in a Model of Ovarian Cancer"
		Burger et al., 1991, <i>Journal of General Virology</i> , 72:359-367, "Stable expression of rabies virus glycoprotein in Chinese hamster ovary cells"
		Cassel et al., 1993, <i>Experimental Hematology</i> , 21:585-591, "Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells"

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

9192.16USWO

Application Number:

09/787,562

Applicant: BINLEY et al.

Filing Date: March 19, 2001

Group Art Unit: Unknown

	Charbord et al., 1996, <i>British Journal of Haematology</i> , 94:449-454 "The purification of CD34+ cells from human cord blood: comparison of separation techniques and cytokine requirements for optimal growth of clonogenic progenitors"
	Chou et al., 1994, <i>Journal of Virology</i> , 68:8304-8311, "Differential Response of Human Cells to Deletions and Stop Codons in the $\gamma_134.5$ Gene of Herpes Simplex Virus"
	Chou et al., 1992, <i>Proc. Natl. Acad.</i> , 89:3266-3270, "The $\gamma_134.5$ gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells"
	Clarke et al., 1998, <i>Journal of Leukocyte Biology</i> , 63: 153-168, "Myeloid-specific gene expression"
	Coffin et al., 1996, <i>Genetic Manipulation of the Nervous System</i> , 99-114, "Herpes Simplex Virus-Based Vectors"
	Cornelisse et al., 1996, <i>Path. Res. Pract.</i> , 192:684-693, "Genes Responsible for Familial Breast Cancer"
	Cosset et al., 1995, <i>Journal of Virology</i> , 69:7430-7436, "High-Titer Packaging Cells Producing Recombinant Retroviruses Resistant to Human Serum"
	Cotton et al., 1993, <i>Journal of Virology</i> , 67:3777-3785, "Chicken Adenovirus (CELO Virus) Particles Augment Receptor-Mediated DNA Delivery to Mammalian Cells and Yield Exceptional Levels of Stable Transformants"
	Dachs et al., 1997, <i>Nature Medicine</i> , 3:515-520, "Targeting gene expression to hypoxic tumor cells"
	Dao et al., 1997, <i>Blood</i> , 89:446-456, "FLT3 Ligand Preserves the Ability of Human CD34 Progenitors to Sustain Long-Term Hematopoiesis in Immune-Deficient Mice after Ex Vivo Retroviral-Mediated Transduction"
	Dunbar et al., 1994, <i>Stem Cells</i> , 12:563-576, "Gene Transfer into Hematopoietic Progenitor and Stem Cells: Progress and Problems"
	Ema et al., 1997, <i>Proc. Natl. Acad.</i> , 94:4273-4278, "A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 α regulates the VEGF expression and is potentially involved in lung and vascular development"
	Emmons et al., 1997, <i>Blood</i> , 89:4040-4046, "Retroviral Gene Transduction of Adult Peripheral Blood or Marrow-Derived CD34 Cells for Six Hours Without Growth Factors or on Autologous Stroma Does Not Improve Marking Efficiency Assessed In Vivo"
	Firth et al., 1995, <i>The Journal of Biological Chemistry</i> , 270:21021-21027, "Hypoxic Regulation of Lactate Dehydrogenase A"

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 9192.16USWO	Application Number: 09/787,562
	Applicant: BINLEY et al.	
	Filing Date: March 19, 2001	Group Art Unit: Unknown

	Firth et al., 1994, <i>Proc. Natl. Acad. Sci.</i> , 91:6496-6500, "Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3' enhancer"
	Fisher et al., 1996, <i>Virology</i> , 217:11-22, "Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis"
	Flamme et al., 1997, <i>Mechanism of Development</i> , 63:51-60, "HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 α and developmentally expressed in blood vessels"
	Fraser et al., 1990, <i>Blood</i> , 76:1071-1076, "Expansion In Virto Retrovirally Marked Totipotent Hematopoietic Stem Cells"
	Frey et al., 1998, <i>Blood</i> , 91:2781-2792, "High-Efficiency Gene Transfer Into Ex Vivo Expanded Human Hematopoietic Progenitors and Precursor Cells by Adenovirus Vectors"
	Ghosh-Choudhury et al., 1986, <i>Gene</i> , 50:161-171, "Human Adenovirus cloning vectors based on infectious bacterial plasmids"
	Giardina et al., 1995, <i>Seminars in Hematology</i> , 32:304-312, "Chelation Therapy in β -Thalassemia: The Benefits and Limitations of Desferrioxamine"
	Gorziglia et al., 1996, <i>Journal of Virology</i> , 70:4173-4178, "Elimination of Both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy"
	Gossen et al., 1992, <i>Proc. Natl. Acad. Sci.</i> , 89:5547-5551, "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters"
	Gossen et al., 1995, <i>Science</i> , 268:1766-1769, "Transcriptional Activation by Tetracyclines in Mammalian Cells"
	Graham et al., 1977, <i>J. gen. Virol.</i> , 36:59-74, "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5"
	Haylock et al., 1992, <i>Blood</i> , 80:1405-1412, "Ex Vivo Expansion and Maturation of Peripheral Blood CD34+ Cells Into the Myeloid Lineage"
	Hearing et al., 1983, <i>Cell</i> , 33:695-703, "The Adenovirus Type 5 E1A Transcriptional Control Region Contains a Duplicated Enhancer Element"
	Inoue et al., 1989, <i>The Journal of Biological Chemistry</i> , 264:14954-14959, "The Human Preproendothelin-1 Gene"
	Jaggar et al., 1997, <i>Human Gene Therapy</i> , 8:2239-2247, "Endothelial Cell-Specific Expression of Tumor Necrosis Factor- α from the KDR or E-Selectin Promoters Following Retroviral Delivery"

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 9192.16USWO	Application Number: 09/787,562
	Applicant: BINLEY et al.	
	Filing Date: March 19, 2001	Group Art Unit: Unknown

	Kim et al., 1998, <i>Journal of Virology</i> , 72:811-816, "Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1"
	Koong et al, 1994, <i>Cancer Research</i> , 54:1425-1430, "Hypoxia Causes the Activation of Nuclear Factor κ B through the Phosphorylation of I κ B α on Tyrosine Residues"
	Krougliak et al., 1995, <i>Human Gene Therapy</i> , 6:1575-1586, "Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants"
	Kuhl et al., 1987, <i>Cell</i> , 50:1057-1069, "Reversible Silencing of Enhancers by Sequencers Derived from the Human IFN- α Promoter"
	Levrero et al., 1991, <i>Gene</i> , 101:195-202, "Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo"
	Lieber et al., 1996, <i>Journal of Virology</i> , 70:8944-8960, "Recombinant Adenovirus with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo"
	Liebert, 1996, <i>Human Gene Therapy</i> , 7:231-253, "Retroviral Mediated Transfer of the cDNA for Human Glucocerebrosidase into Hematopoietic Stem Cells of Patients with Gaucher Disease"
	Lonergan et al., 1998, <i>Molecular and Cellular Biology</i> , 18:732-741, "Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2"
	McLachlan et al., 1991, <i>The Lancet</i> , 337:1304-1309, "Intramuscular desferrioxamine in patients with Alzheimer's disease"
	MacGregor et al., 1991, <i>Methods in Molecular Biology</i> 7:217-235, "Use of E. coli lacZ (β -Galactosidase) as a Reporter Gene"
	MacLean et al., 1991, <i>Journal of General Virology</i> , 72:631-639, "Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence"
	Mađan et al., 1993, <i>Proc. Natl. Acad. Sci.</i> , 90:39283932, "A 24-base-pair sequence 3' to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer"
	Malik et al., 1991, <i>Cancer Research</i> , 51:6643-6649, "Antitumor Activity of γ -Interferon in Ascitic and Solid Tumor Models of Human Ovarian Cancer"
	Malik et al., 1989, <i>Int. J. Cancer</i> , 44:918-925, "Paradoxical Effects of Tumour Necrosis Factor in Experimental Ovarian Cancer"
	Maxwell et al., 1999, <i>Nature</i> , 399:271-275, "The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis"

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 9192.16USWO	Application Number: 09/787,562
	Applicant: BINLEY et al.	
	Filing Date: March 19, 2001	Group Art Unit: Unknown

	Melillo et al., 1997, <i>The Journal of Biochemical Chemistry</i> , 272:12236-12243, "Functional Requirement of the Hypoxia-responsive Element in the Activation of the Inducible Nitric Oxide Synthase Promotor by the Iron Chelator Desferrioxamine"
	Miller et al., 1989, <i>BioTechniques</i> , 7:980-990, "Improved Retroviral Vectors for Gene Transfer and Expression"
	Miyoshi et al., 1998, <i>Journal of Virology</i> , 72:51505157, "Development of a Self-Inactivating Lentivirus Vector"
	Neering et al., 1996, <i>Blood</i> , 88:1147-1155, "Transduction of Primitive Human Hematopoietic Cells With Recombinant Adenovirus Vectors"
	Payne et al., 1998, <i>Journal of Virology</i> , 72:483-487, "Disease Induction by Virus Derived from Molecular Clones of Equine Infectious Anemia Virus"
	Pear et al., 1993, <i>Proc. Natl. Acad. Sci.</i> , 90:8392-8396, "Production of high-titer helper-free retroviruses by transient transfection"
	Peshavaria et al., 1991, <i>Biochem J.</i> , 275:427-433, "Molecular structure of the human muscle-specific enolase gene (ENO3)"
	Piacibello et al., 1997, <i>Blood</i> , 89:2644-2653, "Extensive Amplification and Self-Renewal of Human Primitive Hematopoietic Stem Cells From Cord Blood"
	Rice et al., 1990, <i>Journal of Virology</i> , 64:1704-1715, "Genetic Evidence for Two Distinct Transactivation Functions of the Herpes Simplex Virus α Protein ICP27"
	Santiago-Schwarz et al., 1992, <i>Journal of Leukocyte Biology</i> , 52:274-281, "TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages"
	Soneoka et al., 1995, <i>Nucleic Acids Research</i> , 23:628-633, "A transient three-plasmid expression system for the production of high titer retroviral vectors"
	Semenza et al., 1992, <i>Molecular and Cellular Biology</i> , 12:5447-5454, "A Nuclear Factor Induced by Hypoxia via De Novo Protein Synthesis Binds to the Human Erythropoietin Gene Enhancer at a Site Required for Transcriptional Activation"
	Semenza et al., 1996, <i>The Journal of Biological Chemistry</i> , 271:32529-32537, "Hypoxia Response Elements in the Aldolase E, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1"
	Smith et al., 1992, <i>Virology</i> , 186:74-86, "Evidence That The Herpes Simplex Virus Immediate Early Protein ICP27 Acts Post-Transcriptionally during Infection to Regulate Gene Expression"

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	


FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 9192.16USWO	Application Number: 09/787,562
	Applicant: BINLEY et al.	
	Filing Date: March 19, 2001	Group Art Unit: Unknown

	Stevenson et al., 1987, <i>Cancer Research</i> , 47:6100-6103, "Fate of γ -Interferon-activated Killer Blood Monocytes Adoptively Transferred into the Abdominal Cavity of Patients with Peritoneal Carcinomatosis"
	Stratford-Perricaudet et al., 1992, <i>The American Society for Clinical Investigation, Inc.</i> , 90:626-630, "Widespread Long-term Gene Transfer to Mouse Skeletal Muscles and Heart"
	Takenaka et al., 1989, <i>The Journal of Biological Chemistry</i> 264:2363-2367, "Rat Pyruvate Kinase M Gene"
	Taniguchi et al., 1995, <i>J. Cancer Res. Clin. Oncol.</i> , 121:516-520, "Regulation of the Interferon system and cell growth by the IRF transcription factors"
	Tian et al., 1997, <i>Genes & Development</i> , 11:72-82, "Endothelial PAS domain protein 1 (EPAS10, a transcription factor selectively expressed in endothelial cells"
	Voest et al., 1993, <i>Cancer Chemother. Pharmacol.</i> , 31:357-362, "Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity"
	Wang et al., 1993, <i>Blood</i> , 12:3610-3615, "Desferrioxamine Induces Erythropoietin Gene Expression and Hypoxia-Inducible Factor 1 DNA-Binding Activity: Implications for Models of Hypoxia Signal Transduction"
	Wang et al., 1993, <i>Proc. Natl. Acad. Sci.</i> , 90:4304-4308, "General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia"
	Wang et al., 1995, <i>The Journal of Biological Chemistry</i> , 270:12301-12307, "Purification and Characterization of Hypoxia-inducible Factor 1"
	Ward et al., 1987, <i>Cancer Research</i> , 47:2662-2667, "Intraperitoneal Xenografts of Human Epithelial Ovarian Cancer in Nude Mice"
	Watanabe et al., 1998, <i>Leukemia and Lymphoma</i> , 29:439-451, "Enhancement of Adenovirus-Mediated Gene Transfer to Human Bone Marrow Cells"
	Watanabe et al., 1996, <i>Blood</i> , 87:5032-5039, "Gene Transfer Into Human Bone Marrow Hematopoietic Cells Mediated by Adenovirus Vectors"
	Wei et al., 1994, <i>Human Gene Therapy</i> , 5:969-978, "Experimental Tumor Therapy in Mice Using the Cyclophosphamide-Activating Cytochrome P450 2B1 Gene"
	Wiesener et al., 1998, <i>Blood</i> , 92:2260-2268, "Induction and Endothelial PAS Domain Protein-1 by Hypoxia: Characterization and Comparison With Hypoxia-Inducible Factor-1 α "

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 9192.16USWO	Application Number: 09/787,562
	Applicant: BINLEY et al.	
	Filing Date: March 19, 2001	Group Art Unit: Unknown

		Yeh et al., 1996, <i>Journal of Microbiology</i> , 70:529-565, "Efficient Dual Transcomplementation of Adenovirus E1 and E4 Regions from a 293-Derived Cell Line Expressing a Minimal E4 Functional Unit"
		Zacharova et al., 1997, <i>AIDS Research and Human Retroviruses</i> 13:719-724, "DNA Sequence Analysis of the Long Terminal Repeat of the C Subtype of Human Immunodeficiency Virus Type 1 from Southern Africa Reveals a Dichotomy between B Subtype and African Subtypes on the Basis of Upstream NF-IL6 Motif"
		Zhang et al., 1994, <i>Molecular and Cellular Biology</i> , 14:8085-8095, "Identification of a Region Which Directs the Monocytic Activity of the Colony-Stimulating Factor 1 (Macrophage Colony-Stimulating Factor) Receptor Promoter and Binds PEBP2/CBF (AML1)"
		International Search Report for PCT/GB99/03181



EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	